このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

高リスク神経芽細胞腫患者における経口メトロノミック サイトキサンによる同種腫瘍細胞ワクチン接種 (ATOMIC)

2026年9月30日 更新者:Helen Heslop、Baylor College of Medicine

高リスク神経芽細胞腫 (ATOMIC) 患者における経口メトロノミック サイトキサンによる同種腫瘍細胞ワクチン接種を使用した第 I/II 相試験

Neuroblastoma is the second most common solid tumor seen in children, but causes approximately 15% of childhood cancer deaths each year. Patients with high-risk disease require treatment with a combination of chemotherapy, surgery, radiation, and stem cell transplant; however, many will have their disease come back within 3 years. Due to this high rate of relapse, this study is being done to investigate an experimental treatment option for children whose disease has returned.

This clinical trial is for patients with neuroblastoma that has either come back after treatment or never went away in the first place. A series of immunizations will be administered using a tumor vaccine and add low-dose chemotherapy to be taken by mouth on a daily basis. The hope is that the vaccine will cause the immune system to recognize and kill more types of neuroblastoma tumors. Additionally, the immunizations will be combined with daily low dose chemotherapy. Daily low-dose chemotherapy, also know as metronomic chemotherapy, works by attacking the blood vessels that allow tumors to grow. Using metronomic doses of a drug called cytoxan can also decrease T regulatory cells, a specific type of cell that tumors use to hide from the immune system.

The purpose of this study is to test the safety and anti-tumor effect of the tumor cell vaccination plus low dose, metronomic chemotherapy in treating patients with relapsed/refractory neuroblastoma.

調査の概要

詳細な説明

WHAT IS THE OVERALL TREATMENT PLAN AND HOW MANY VACCINATIONS WILL THE PATIENT RECEIVE? There will be several injections of the vaccine scheduled. The first injection will be given 3 days after starting oral cytoxan. The 2nd to 4th injections will be given approximately every 14 days after the previous vaccine. During this time, the patient will be taking oral cytoxan once a day except on the day of and 4 days following the vaccine. Two to 3 weeks after the 4th vaccine, the patient will have a complete evaluation of their disease. If the scans and lab tests show that the patient has not had any serious side-effects, they will be eligible to receive 4 additional vaccinations given at 3 week intervals. The disease will be re-evaluated again after vaccine numbers 6 and 8. If the patient is able to complete the entire study, they will have received a total of 8 vaccinations and the last dose of oral cytoxan will be 1 month after the 8th vaccination. Total time duration for participating in this study is 15 years (treatment portion within year 1 and follow up during years 2-15).

Neuroblastoma vaccinations are given like many other vaccines. They will be given subcutaneously. The injections will be 1/10th of a teaspoon.

MEDICAL TESTS BEFORE STARTING TREATMENT:

Before starting low dose chemotherapy plus oral cytoxan, patients will receive a series of standard medical tests:

  • Physical exam
  • Blood tests to measure blood cells, blood salts, kidney and liver function
  • Measurements of their disease (CT or MRI of the primary tumor site and any locations of tumor spread; MIBG or Bone scan; Chest X-ray if they did not have a CT of the chest; and bone marrow studies if the patient has known bone marrow disease)
  • Baseline testing of immune function
  • Pregnancy testing will be performed on females of child bearing age

MEDICAL TESTS DURING AND AFTER TREATMENT:

Prior to each vaccine dose, the patient will receive:

  • Physical exam
  • Blood tests to measure blood cells, blood salts, kidney and liver function
  • Measurements of the disease (CT or MRI of the primary tumor site and any locations of tumor spread; MIBG or Bone scan; Chest X-ray if they did not have a CT of the chest; and bone marrow studies if they have known bone marrow disease) after the 4th, 6th and 8th vaccine.
  • Testing of immune function
  • Pregnancy testing will be performed again on females of child bearing age prior to the 5th vaccine

To learn more about the way the vaccine is stimulating the immune cells, we will collect blood prior to each vaccination and at scheduled time points until 3 months after the last vaccine treatment. The total amount of blood to be collected on any day is no more than 2 ounces, but will depend upon the weight. This volume is considered safe in teens and adults, but may be decreased if the patient is anemic. On days when the patient receives the vaccine, blood will be taken before the cells are given.

研究の種類

介入

入学 (実際)

11

段階

  • フェーズ2
  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Texas
      • Houston、Texas、アメリカ、77030
        • Texas Children's Hospital

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 子
  • 大人
  • 高齢者

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

INCLUSION CRITERIA:

  • Histologically proven high risk neuroblastoma in first or subsequent relapse or with primary refractory disease or inability to complete standard therapy
  • Age less than 21 at time of initial diagnosis
  • Life expectancy 12 weeks or greater
  • Karnofsky or Lansky score of 50 or greater
  • Platelet count of 50,000/ul or greater
  • ANC greater than 750/ul
  • Alk Phos level less than 2.5 x upper limit of normal
  • Bilirubin less than 2x normal
  • AST less than 3x normal
  • Hgb 8.0 or greater
  • Creatinine 2 x ULN or less OR GFR greater than 40 ml/min/1.73 m2
  • Patient has recovered from last chemotherapy or investigational therapy prior to study enrollment
  • Women of child-bearing potential must not be pregnant and take/use effective birth control while participating in the study.

EXCLUSION CRITERIA:

  • Due to the unknown effects of this therapy on a fetus, pregnant women will be excluded from this research
  • Women who are breast-feeding
  • Known HIV positive subjects since treatment may be immunosuppressive
  • Severe intercurrent infection or uncontrolled condition including, but not limited to ongoing or active infection, symptomatic heart failure, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  • Previous use of oral cytoxan for more than 2 consecutive months within the last 6 months
  • Patients currently receiving any investigational agents or have received any tumor vaccines within the previous six months
  • Patients, who in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Treatment Plan

Neuroblastoma Vaccine (unmodified SKNLP, with gene-modified SJNB-JF-IL2 and SJNB-JF-LTN neuroblastoma cells) and Cytoxan (Cyclophosphamide)

1x10^7cells/m2 each of unmodified SKNLP, with gene-modified SJNB-JF-IL2 and SJNB-JF-LTN neuroblastoma cells will be given by subcutaneous injection while suspended in Ringers solution with 5% HSA in a single syringe in a volume of up to 1 ml.

Vaccines will be given on day 0 of week 0 and then on day 0 (+ 72 hours) of weeks 2, 4, 6, 9, 12, 16, 20.

Cells will be administered as a subcutaneous injection over 1 minute using a 21-gauge needle. Procedural pain control methods may be used per institutional protocol.

他の名前:
  • 遺伝子改変を伴うSKNLP。 SJNB-JF-IL2 & SJNB-JF-LTN neurobl.細胞

Metronomic oral cytoxan will start 72 hours prior to the first vaccination at a dose of 50 mg/m2/day. Cytoxan will be held on the day of vaccine administration and for the next 96 hours. After the first vaccine, patients will take 25 mg/m2/day as outlined on the roadmap.

他の名前:
  • シクロホスファミド

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Number of Participants with Adverse Events as a Measure of Safety and Tolerability
時間枠:week 30

Phase I Primary Objective: Evaluate the safety of fixed dose oral cytoxan administered metronomically to coincide with repeated immunizations of gene-modified, IL-2/lymphotactin secreting SJNB-JF-IL2 and SJNB-JF-LTN cells co-administered with unmodified SKNLP neuroblastoma cell lines in patients with a history of relapsed/refractory high-risk neuroblastoma.

week 30

二次結果の測定

結果測定
メジャーの説明
時間枠
Participants with T-cell changes as a Measure of Immune Response
時間枠:15 years

Phase I Secondary Objective: Evaluate the immune response to combination metronomic chemotherapy and allogeneic tumor cell immunizations.

15 years
Number of Participants with Disease Progression as a Measure of Efficacy
時間枠:10 weeks

Phase II Primary Objective: Evaluate time to progression after administration of combination metronomic chemotherapy and allogeneic tumor cell immunizations in patients with a history of relapsed/refractory high-risk neuroblastoma.

10 weeks

その他の成果指標

結果測定
メジャーの説明
時間枠
Analysis of Immunologic Measurements
時間枠:15 years

Phase II Secondary Objectives:

  1. Evaluate changes in T regulatory cell absolute number, percentages, and suppressive function after the use of metronomic low-dose oral cytoxan with allogeneic neuroblastoma tumor cell immunizations.
  2. Evaluate the alterations in angiogenic biomarkers related to fixed dose oral cytoxan and repeated immunizations with allogeneic tumor cell immunizations.
15 years

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Helen Heslop, MD、Baylor College of Medicine
  • 主任研究者:Malcolm Brenner, MD、The Methodist Hospital Research Institute

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2010年9月1日

一次修了 (実際)

2012年7月1日

研究の完了 (推定)

2027年6月1日

試験登録日

最初に提出

2010年8月16日

QC基準を満たした最初の提出物

2010年8月30日

最初の投稿 (推定)

2010年9月1日

学習記録の更新

投稿された最後の更新 (実際)

2026年10月2日

QC基準を満たした最後の更新が送信されました

2026年9月30日

最終確認日

2026年9月1日

詳しくは

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する